New and emerging lipid-modifying drugs to lower LDL cholesterol

Constantine E. Kosmas; Dafni Pantou; Andreas Sourlas; Evangelia J. Papakonstantinou; Rogers Echavarria Uceta; Eliscer Guzman

doi:10.7573/DIC.2021-8-3

New and emerging lipid-modifying drugs to lower LDL cholesterol

Constantine E. Kosmas
, Dafni Pantou
, Andreas Sourlas
, Evangelia J. Papakonstantinou
, Rogers Echavarria Uceta
, Eliscer Guzman

Research output: Contribution to journal › Review article › peer-review

26 Scopus citations

Abstract

Cardiovascular disease (CVD) represents the leading cause of death worldwide. The role of low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of atherosclerosis and CVD has been well recognized. Statins are the standard of care for the management of hypercholesterolaemia, and their effectiveness in lowering LDL-C and reducing CVD risk in both primary and secondary prevention has been well established. However, several patients fail to attain optimal LDL-C goals or are intolerant to statins, especially at high doses. PCSK9 inhibitors, bempedoic acid, inclisiran, ANGPTL3 inhibitors, PPARβ/δ agonists and LXR agonists are novel or upcoming LDL-C-lowering agents that have shown promising beneficial results. This review aims to present and discuss the current clinical and scientific data pertaining to the new and emerging lipid-modifying LDL-C-lowering drugs.

Original language	English
Article number	83
Journal	Drugs in Context
Volume	10
DOIs	https://doi.org/10.7573/DIC.2021-8-3
State	Published - 2021
Externally published	Yes

Keywords

ANGPTL3 inhibitors
Bempedoic acid
Cardiovascular disease
Inclisiran
LDL-C-lowering
LXR agonists
PCSK9 inhibitors
PPARβ/δ agonists

Access to Document

10.7573/DIC.2021-8-3

Cite this

@article{10edb593b7674648ad80fe17ed7a341f,

title = "New and emerging lipid-modifying drugs to lower LDL cholesterol",

abstract = "Cardiovascular disease (CVD) represents the leading cause of death worldwide. The role of low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of atherosclerosis and CVD has been well recognized. Statins are the standard of care for the management of hypercholesterolaemia, and their effectiveness in lowering LDL-C and reducing CVD risk in both primary and secondary prevention has been well established. However, several patients fail to attain optimal LDL-C goals or are intolerant to statins, especially at high doses. PCSK9 inhibitors, bempedoic acid, inclisiran, ANGPTL3 inhibitors, PPARβ/δ agonists and LXR agonists are novel or upcoming LDL-C-lowering agents that have shown promising beneficial results. This review aims to present and discuss the current clinical and scientific data pertaining to the new and emerging lipid-modifying LDL-C-lowering drugs.",

keywords = "ANGPTL3 inhibitors, Bempedoic acid, Cardiovascular disease, Inclisiran, LDL-C-lowering, LXR agonists, PCSK9 inhibitors, PPARβ/δ agonists",

author = "Kosmas, \{Constantine E.\} and Dafni Pantou and Andreas Sourlas and Papakonstantinou, \{Evangelia J.\} and Uceta, \{Rogers Echavarria\} and Eliscer Guzman",

note = "Publisher Copyright: Copyright {\textcopyright} 2021 Kosmas CE, Pantou D, Sourlas A, Papakonstantinou EJ, Echavarria Uceta R, Guzman E.",

year = "2021",

doi = "10.7573/DIC.2021-8-3",

language = "English",

volume = "10",

journal = "Drugs in Context",

issn = "1745-1981",

publisher = "Bioexcel Publishing LTD",

}

TY - JOUR

T1 - New and emerging lipid-modifying drugs to lower LDL cholesterol

AU - Kosmas, Constantine E.

AU - Pantou, Dafni

AU - Sourlas, Andreas

AU - Papakonstantinou, Evangelia J.

AU - Uceta, Rogers Echavarria

AU - Guzman, Eliscer

PY - 2021

Y1 - 2021

N2 - Cardiovascular disease (CVD) represents the leading cause of death worldwide. The role of low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of atherosclerosis and CVD has been well recognized. Statins are the standard of care for the management of hypercholesterolaemia, and their effectiveness in lowering LDL-C and reducing CVD risk in both primary and secondary prevention has been well established. However, several patients fail to attain optimal LDL-C goals or are intolerant to statins, especially at high doses. PCSK9 inhibitors, bempedoic acid, inclisiran, ANGPTL3 inhibitors, PPARβ/δ agonists and LXR agonists are novel or upcoming LDL-C-lowering agents that have shown promising beneficial results. This review aims to present and discuss the current clinical and scientific data pertaining to the new and emerging lipid-modifying LDL-C-lowering drugs.

AB - Cardiovascular disease (CVD) represents the leading cause of death worldwide. The role of low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of atherosclerosis and CVD has been well recognized. Statins are the standard of care for the management of hypercholesterolaemia, and their effectiveness in lowering LDL-C and reducing CVD risk in both primary and secondary prevention has been well established. However, several patients fail to attain optimal LDL-C goals or are intolerant to statins, especially at high doses. PCSK9 inhibitors, bempedoic acid, inclisiran, ANGPTL3 inhibitors, PPARβ/δ agonists and LXR agonists are novel or upcoming LDL-C-lowering agents that have shown promising beneficial results. This review aims to present and discuss the current clinical and scientific data pertaining to the new and emerging lipid-modifying LDL-C-lowering drugs.

KW - ANGPTL3 inhibitors

KW - Bempedoic acid

KW - Cardiovascular disease

KW - Inclisiran

KW - LDL-C-lowering

KW - LXR agonists

KW - PCSK9 inhibitors

KW - PPARβ/δ agonists

UR - https://www.scopus.com/pages/publications/85119612809

U2 - 10.7573/DIC.2021-8-3

DO - 10.7573/DIC.2021-8-3

M3 - Review article

AN - SCOPUS:85119612809

SN - 1745-1981

VL - 10

JO - Drugs in Context

JF - Drugs in Context

M1 - 83

ER -

New and emerging lipid-modifying drugs to lower LDL cholesterol

Abstract

Keywords

Access to Document

Fingerprint

Cite this